GLP-1 Drugs & Heart Health: Morning Exercise Benefits Revealed

The benefits of GLP-1 medications for people with type 2 diabetes appear to diminish rapidly once the drugs are stopped, even after just a few months, increasing the risk of cardiovascular events. This finding, reported in recent research, underscores the importance of consistent medication adherence for those managing both diabetes and heart health. Simultaneously, new data suggests that morning exercise may offer unique cardiovascular benefits, potentially maximizing the impact of physical activity.

GLP-1 Discontinuation and Cardiovascular Risk

GLP-1 receptor agonists, a class of drugs including Ozempic (Novo Nordisk NOVOb.CO) and Trulicity/Mounjaro (Eli Lilly LLY.N), have become increasingly common in the treatment of type 2 diabetes, in part due to their demonstrated ability to reduce the risk of adverse cardiac events. However, a new analysis reveals that interrupting treatment – even for a relatively short period – can erode these protective effects.

Researchers, led by Dr. Ziyad Al-Aly of the Veterans Affairs Saint Louis Health Care System, analyzed the medical records of over 333,000 adults with type 2 diabetes treated with either GLP-1 medications or sulfonylureas. The study, utilizing data from a US Veterans Affairs database spanning three years, found a clear correlation between continued GLP-1 use and reduced cardiovascular risk – an 18% decrease compared to those taking sulfonylureas. However, stopping GLP-1 treatment for as little as six months began to negate this benefit, increasing risk by 4% compared to continued use. After two years off the medication, the cardiovascular risk increased by 22%.

Dr. Al-Aly emphasized that while resuming treatment can partially restore some cardioprotective effects, it doesn’t fully reverse the damage. He noted that patients often discontinue these medications due to side effects, shortages, or cost concerns. “When they stop, it’s not just the weight that comes back. They experience a resurgence of inflammation, blood pressure, and cholesterol,” he stated. He described this metabolic reversal as a “metabolic bounceback,” potentially harmful to cardiac health.

This research, published in BMJ Medicine, highlights a critical consideration for both patients and clinicians. It suggests that the benefits of GLP-1 medications are not sustained during treatment gaps, and that consistent adherence is crucial for maximizing cardiovascular protection. It’s important to note that this study demonstrates an association, and further research is needed to fully understand the underlying mechanisms driving this effect.

Morning Exercise and Cardiometabolic Health

Alongside the findings regarding GLP-1 medications, new research suggests a potential advantage to exercising earlier in the day. Researchers followed 14,000 US volunteers who shared heart rate data collected from Fitbit devices. They found that individuals who regularly exercised in the morning were 31% less likely to develop coronary artery disease compared to those who exercised later.

The benefits extended beyond heart disease. Morning exercisers likewise showed an 18% lower risk of hypertension, a 21% lower risk of high cholesterol, a 30% lower risk of type 2 diabetes, and a 35% lower risk of obesity, regardless of the total amount of daily physical activity. The study indicated that exercising between 7:00 and 8:00 AM was associated with the lowest risks of coronary artery disease.

These findings, slated to be presented at the annual meeting of the American College of Cardiology, represent the first large-scale study to examine the timing of exercise in relation to cardiometabolic health using long-term wearable device data. Researchers caution that the study does not prove a causal link between morning exercise and improved health outcomes. Biological factors like hormones, sleep, and genetics, as well as behavioral and psychological factors, could also play a role.

The Role of Wearable Technology in Health Research

The study’s lead author, Prem Patel, a medical student at the University of Massachusetts Chan School of Medicine, highlighted the potential of wearable technology to advance health research. “In the past, researchers have primarily focused on the quantity of physical activity,” Patel explained. “Now that one in three Americans owns a wearable device, we have the opportunity to examine exercise at a minute-by-minute level, opening up many doors for new analyses.”

Implications for Patient Care and Public Health

These two studies, while distinct, converge on the importance of proactive health management. For individuals with type 2 diabetes, maintaining consistent medication adherence, particularly with GLP-1 receptor agonists, appears critical for sustained cardiovascular protection. The research underscores the need for open communication between patients and healthcare providers to address barriers to medication adherence, such as side effects, cost, and access.

Regarding exercise, the findings suggest that incorporating physical activity into the morning routine may offer additional cardiometabolic benefits. While all exercise is beneficial, timing may be a factor worth considering. However, it’s important to remember that this research is preliminary, and more studies are needed to confirm these findings and determine the optimal timing and intensity of exercise for different populations.

Ongoing Research and Future Directions

Further research is needed to fully elucidate the mechanisms underlying the observed effects of GLP-1 discontinuation and the timing of exercise. Studies investigating the impact of different durations of treatment interruption, as well as the long-term effects of morning exercise, are warranted. Research exploring the interplay between medication adherence, exercise timing, and other lifestyle factors could provide a more comprehensive understanding of cardiovascular health. The American College of Cardiology meeting this month will likely provide further insights into these areas.

As data from wearable devices continues to accumulate, One can expect to see even more nuanced insights into the relationship between lifestyle factors and health outcomes. This evolving landscape promises to inform more personalized and effective strategies for preventing and managing cardiovascular disease.